LL-37 is a cationic antimicrobial peptide (AMP) naturally produced by immune and epithelial cells as part of the body’s innate defense system. It plays a role not only in direct antimicrobial activity but also in tissue repair, immune regulation, and wound healing. At Orion Biomedica, LL-37 is offered under individualized clinical protocols, especially in cases involving chronic inflammation, biofilm-associated infections, and recalcitrant wounds.
📌 Learn more about LL-37’s role in antimicrobial defense and immunomodulation.
Mechanisms of Action
LL-37 is part of the human cathelicidin family and functions as a host defense peptide (HDP). It has been shown in preclinical and translational studies to:
- Exert broad-spectrum antimicrobial activity against bacteria, viruses, and fungi
- Disrupt microbial biofilms, especially in chronic infections
- Modulate inflammatory cytokine activity and immune cell signaling
- Stimulate wound healing, angiogenesis, and epithelial cell migration
- Regulate barrier function in skin, mucosa, and respiratory tissue
Administration is typically topical for dermatologic and wound cases, or intranasal in ENT applications. Subcutaneous injection may be considered in systemic immune modulation contexts.
📌 See research on LL-37’s dual role in microbial defense and epithelial regeneration.
Individualized Therapeutic Application
LL-37 is considered at Orion Biomedica for patients requiring adjunctive support in conditions where barrier integrity, microbial persistence, or chronic immune activation is involved. Applications may include:
- Chronic wounds or delayed post-surgical healing
- Biofilm-related sinus infections or recurrent tonsillitis
- Skin conditions with inflammatory or microbial components
- Mucosal defense enhancement in recurrent infection states
- Adjuvant care in immunologically complex or post-viral syndromes
Each protocol is tailored based on clinical findings, laboratory testing, and patient response.
Therapeutic Fields of Research Interest and Administration Protocols
LL-37 is under investigation in dermatology, ENT, immunology, and infectious disease for its host defense, anti-inflammatory, and pro-repair properties. At Orion Biomedica, use is restricted to medically supervised settings and delivered in appropriate formats per indication.
🔬 LL-37 Protocol Matrix
| Therapeutic Area | Primary Aim | Recommended Administration Route | Clinical Setting |
|---|---|---|---|
| Dermatology / Wound Care | Chronic wound support and tissue healing | Topical gel or hydrogel dressing | Outpatient wound care |
| ENT / Sinus Infections | Biofilm modulation and epithelial protection | Intranasal spray or drops | Outpatient ENT setting |
| Post-surgical Recovery | Accelerated wound closure and scar minimization | Topical or peri-incisional application | Surgical aftercare setting |
| Immunology | Immune tone balancing and inflammation support | Subcutaneous injection (case-dependent) | Outpatient clinic |
| Infectious Disease Recovery | Support in mucosal barrier repair and host defense | Topical or systemic (as appropriate) | Outpatient clinic |
📌 Explore clinical data on LL-37 in chronic wound management and mucosal healing.
Clinical Framework
LL-37 peptide therapy at Orion Biomedica is:
- Delivered only after full clinical evaluation
- Administered by qualified medical staff in licensed settings
- Framed as an experimental and supportive intervention
- Used in cases where conventional therapy has proven insufficient or suboptimal
All applications are based on informed consent and are not presented as primary treatments for infection or autoimmune disease.
Regulatory Notice
LL-37 is not registered as a medicinal product by the European Medicines Agency (EMA) or the Bulgarian Drug Agency (BDA). It is used under experimental frameworks in accordance with clinical judgment and ethical medical practice. All patients are informed of its regulatory status and limited clinical validation prior to therapy.
📞 For further information or to request a consultation, please contact Orion Biomedica.